作者: Peter Reimer
DOI: 10.2147/CMAR.S85351
关键词: Oncology 、 Refractory 、 Belinostat 、 Internal medicine 、 Peripheral T-cell lymphoma 、 T-cell lymphoma 、 Conventional chemotherapy 、 Medicine 、 Bioinformatics 、 Chemotherapy 、 Anaplastic lymphoma kinase 、 Anaplastic large-cell lymphoma
摘要: Peripheral T-cell lymphomas (PTCL) represent a heterogeneous group of rare malignancies that with the exception anaplastic lymphoma kinase expressing large cell lymphoma, share poor outcome after standard (eg, anthracycline-based) chemotherapy. Most patients are either refractory to initial therapy or eventually relapse. Randomized studies for relapsed/refractory PTCL not available, however, recently published data show conventional chemotherapy has very limited efficacy in salvage setting. Thus, novel drugs urgently needed improve this Belinostat, pan-histone deacetylase inhibitor, demonstrated meaningful and favorable toxicity profile two single-arm Phase II trials on 153 PTCL. The conclusive results led an accelerated approval by US Food Drug Administration. present review summarizes clinical available belinostat, its current role, future perspectives.